Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Double-pronged attack could treat common children’s cancer

A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become resistant to treatment, according to a new study.  

A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become resistant to treatment, according to a new study.  Scientists at The Institute of Cancer Research, London, found that combining two separate molecularly targeted therapies could stop processes driving growth in a cancer called rhabdomyosarcoma, a major cause of cancer death in children. The drugs, called AZD8055 and AZD6244, block two different signalling pathways involved in cancer growth €“ acting like road-blocks on two separate routes that cancers could otherwise use to

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy